Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma

Research output: Contribution to journalArticlepeer-review


The association of cisplatin plus cyclophosphamide (PC) is considered to be the standard medical treatment for advanced ovarian carcinoma, while the role of doxorubicin in combination with cisplatin and cyclophosphamide (PAC regimen) is still controversial. Recently, four randomized clinical trials evaluating PC versus PAC regimen have been published. None of these studies showed a convincing advantage for the addition of doxorubicin to PC. By pooling the data from the 1200 or so patients included in these four studies and analyzing them with the statistical technique of metanalysis, a statistical benefit for PAC over PC is demonstrated in terms of pathologic complete response rate (30 vs 23%, P = 0.01) and 6-year survival rate (27 vs 21%, P = 0.01).

Original languageEnglish
Pages (from-to)152-155
Number of pages4
JournalBulletin du Cancer
Issue number2
Publication statusPublished - 1993


  • Anthracyclines
  • Meta-analysis
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma'. Together they form a unique fingerprint.

Cite this